Reported about 2 months ago
In response to the FDA's recent rejection of its MDMA-based PTSD treatment, Lykos Therapeutics announced it will lay off about 75% of its employees, approximately 100 individuals. The company's founder, Rick Doblin, is also stepping down from the board. Lykos plans to appoint David Hough to lead the clinical development of its MDMA capsules and aims to resubmit its application to the FDA for approval.
Source: YAHOO